NEW YORK ( TheStreet) -- Any decent management team will tell you that turning around a struggling business is never easy. If that company happens to be in the realm of medical device technology, case studies are rampant.
Companies like Boston Scientific (BSX), Johnson & Johnson (JNJ) and Stryker (SYK) have gone through several years of "reconstructive surgery" to nurse their businesses back to health. And the Street has been anything but patient or forgiving during that span. To that end, it's a little surprising the degree to which the benefit of the doubt is being granted to Smith & Nephew (SNN - Get Report).
Over the past couple of years, Smith & Nephew's growth has underperformed industry peers like Zimmer (ZMH) and Stryker. The company has steadily lost market share to (among others) Johnson & Johnson in areas like orthopedic implants for hips and knees. And this occurred as management dealt with problems related to the recalls of R3 Acetabular system linked to bone and muscle complications in patients.
Smith & Nephew has not been alone in product recalls. Johnson & Johnson, Stryker and St. Jude Medical
(STJ) have dealt with similar issues. Smith & Nephew has not. Today, Smith & Nephew is regarded as one of the best medical device companies on the market.
I haven't heard anyone say this, but there's a lot of evidence pointing to management's deal for Healthpoint Biotherapeutics two years ago as the cause for this turnaround.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts